Open-Label Multicenter Phase 1b/2 Study of Nanatinostat + Valganciclovir in Patients With Advanced Epstein-Barr Virus-Positive Solid Tumors and in Combination With Pembrolizumab in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma
Latest Information Update: 14 Mar 2025
At a glance
- Drugs Nanatinostat/valganciclovir combination therapy (Primary) ; Pembrolizumab (Primary) ; Valganciclovir (Primary)
- Indications Carcinoma; Gastric cancer; Leiomyosarcoma; Nasopharyngeal cancer; Solid tumours
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Viracta Therapeutics
Most Recent Events
- 10 Jan 2025 Status changed from active, no longer recruiting to discontinued.
- 10 Jan 2025 According to ClinicalTrials.gov: US National Institutes of Health, Terminated due to Sponsor Decision
- 01 Oct 2024 According to a Viracta Therapeutics media release, the company determined the recommended Phase 2 dose in patients with advanced EBV+ solid tumors.